Smart Healthcare

Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study

“`html

Enhanced Treatment for Relapsed T-lymphoblastic Leukemia/Lymphoma

Patients with relapsed or refractory T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) often face limited treatment options. A new study evaluated a combination therapy using daratumumab (Dara) and venetoclax (Ven) with aclarubicin, cytarabine, granulocyte colony-stimulating factor, and etoposide (CAGE) for these patients.

Key Findings:

  • The combined therapy showed a promising remission rate of 57.1% and a complete remission rate of 47.6% in patients.
  • Patients with the early T-cell precursor (ETP) subtype had a significantly higher remission rate compared to non-ETP patients (100% vs. 44.4%).
  • The treatment was well-tolerated by the patients, indicating its safety and tolerability.

This study suggests that the combination of Dara and Ven with the CAGE regimen could offer a valuable treatment option for patients with relapsed or refractory T-ALL/LBL, especially for those with the ETP subtype.

Full Clinical Trial Report
“`

AI Products for Business or Try Custom Development

AI Sales Bot

Welcome AI Sales Bot, your 24/7 teammate! Engaging customers in natural language across all channels and learning from your materials, it’s a step towards efficient, enriched customer interactions and sales

AI Document Assistant

Unlock insights and drive decisions with our AI Insights Suite. Indexing your documents and data, it provides smart, AI-driven decision support, enhancing your productivity and decision-making.

AI Customer Support

Upgrade your support with our AI Assistant, reducing response times and personalizing interactions by analyzing documents and past engagements. Boost your team and customer satisfaction

AI Scrum Bot

Enhance agile management with our AI Scrum Bot, it helps to organize retrospectives. It answers queries and boosts collaboration and efficiency in your scrum processes.